Here are the 10-K annual reports from Palatin Technologies, Inc. (PTN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTN filings page.
Palatin Technologies (PTN) is prioritizing MC4R agonists for obesity. It plans a Phase 1 study of its long-acting peptide in the first half of calendar 2027; for its oral small molecule, it plans IND-enabling work in the first half and a Phase 1 study in the second half of 2027. Both programs focus on rare neuroendocrine diseases and MC4R pathway disorders.
Boehringer Ingelheim paid €2.0 million ($2.3 million) upfront in August 2025 and €5.5 million ($6.5 million) after a September 2025 research milestone under a retinal-disease agreement; the agreement provides for up to €280,000,000 (approximately $328,000,000) in contingent milestones, plus royalties. Altanispac received exclusive rights to PL9643 for dry eye disease, and Palatin recognized $3,751,122 in fiscal 2026 license revenue through non-cash debt cancellation. A Phase 2 bremelanotide-tirzepatide study reported 4.4% weight reduction versus 1.6% for placebo over eight weeks.
At June 30, 2026, Palatin had $7.5 million in cash and cash equivalents and $1.8 million in current liabilities. The company concluded that substantial doubt existed about its ability to continue as a going concern for one year from the financial statements’ issuance date and said it needs additional funding for development and clinical trials.